Navigation Links
ACD Wins $3 Million Grant From National Cancer Institute to Develop Its CTCscope™ System for Detection and Molecular Analysis of Circulating Tumor Cells
Date:10/8/2010

HAYWARD, Calif., Oct. 8 /PRNewswire/ -- Advanced Cell Diagnostics, Inc. (ACD) was awarded a three-year, $3 million grant from National Cancer Institute (NCI) under its SBIR Phase II Bridge Award. This grant will support ACD's continuing effort to develop its proprietary CTCscope™ system capable of automatic detection and molecular characterization of circulating tumor cells (CTCs). CTCs are the rare tumor cells detached from solid tumors and circulating in cancer patients' blood.

"We are very grateful for the continued support from NCI. The previous Phase I and Phase II grants have helped ACD to develop the underlying RNAscope™ technology, which has since been translated successfully into Research Use Only products for in situ detection of RNA biomarkers in FFPE samples," commented by Dr. Yuling Luo, President & CEO of ACD.  "Given how few of these grants are given, the award is a further validation of the strength of our technology to uniquely fulfill a critical unmet clinical need in cancer management." ACD has since been featured as one of the NCI SBIR Success Stories (http://sbir.cancer.gov/success/stories/acd/acd.asp).

In this latest grant, ACD will work with a multidisciplinary team from four leading institutions to further advance CTCscope™ into an automated system and conduct clinical studies to demonstrate its clinical utility. Collaborators include Dr. Paul Goodwin of Applied Precision, Drs. Hope Rugo and John Park of University of California San Francisco, Prof. David Krag of University of Vermont, and Prof. Charles Coombes of Imperial College London.

About CTCscope™:

ACD's CTCscope™ system is based on its proprietary in situ RNA detection platform RNAscope™, which enables highly sensitive and specific detection of all types of CTCs without the need for EpCAM-based enrichment. Importantly, CTCscope™ is the only technology that detects those CTCs still alive while circulating in cancer patients' blood. These are the rare tumor cells that have the potential to metastasize to distant sites and thus are the targets of chemo- and targeted therapies. CTCscope™ identifies the molecular phenotypes of CTCs for guiding treatment decisions and allows real-time monitoring of therapy response.

About Advanced Cell Diagnostics (www.acdbio.com)

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. The company's products and services are based on its proprietary RNAscope™ technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners' targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management.Contact: Steve Chen, Ph.D. Chief Operating Officer (510) 576-8800 ext 102 schen@acdbio.com
'/>"/>

SOURCE Advanced Cell Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. Atritech Announces Completion of a $22 Million Equity Financing
3. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
4. EntreMed Raises $20 Million to Support Clinical Development Program
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
7. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
8. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
9. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
10. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
11. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):